HDAC9 and cancer: Epigenetically silenced RARβ has been shown to be re-expressed in the presence of histone deacetylase (HDAC) inhibitors and DNA methyltransferase inhibitors (DNMT) inhibitors in RARβ2 silent cancer cells [33].